Business Combinations - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended			0 Months Ended		1 Months Ended	3 Months Ended			12 Months Ended						12 Months Ended
	Sep. 27, 2014	Mar. 30, 2013	Sep. 27, 2014	Sep. 28, 2013	Sep. 29, 2012	Dec. 31, 2012 Chindex Medical Limited [Member]	May 31, 2013 SenoRx, Inc [Member]	Aug. 01, 2012 Gen-Probe Incorporated [Member]	Jun. 29, 2013 Gen-Probe Incorporated [Member]	Mar. 30, 2013 Gen-Probe Incorporated [Member]	Dec. 29, 2012 Gen-Probe Incorporated [Member]	Sep. 27, 2014 Gen-Probe Incorporated [Member] project	Sep. 28, 2013 Gen-Probe Incorporated [Member]	Sep. 29, 2012 Gen-Probe Incorporated [Member] project	Jan. 03, 2013 Gen-Probe Incorporated [Member]	Sep. 28, 2013 Gen-Probe Incorporated [Member] Minimum [Member]	Sep. 28, 2013 Gen-Probe Incorporated [Member] Maximum [Member]	Sep. 27, 2014 Gen-Probe Incorporated [Member] Property, Plant and Equipment [Member]	Sep. 27, 2014 Gen-Probe Incorporated [Member] Land and Buildings [Member]	Sep. 27, 2014 Developed Technology [Member] Gen-Probe Incorporated [Member]	Sep. 27, 2014 Customer Contract [Member] Gen-Probe Incorporated [Member]	Sep. 27, 2014 Trade Names [Member] Gen-Probe Incorporated [Member]
Business Acquisition [Line Items]
Net purchase price						$ 4,400,000	$ 2,400,000	$ 3,972,200,000
Cash paid per share								$ 82.75
Amount paid to shareholders								3,800,000,000
Amount paid to equity award holders								169,000,000
Net debt obtained by the Company to finance the acquisition								3,480,000,000
Direct transaction costs incurred								34,300,000
Remaining fair value of stock options assumed to be recognized as compensation expense												23,200,000
Vesting period			3 years									3 years 6 months
Risk free interest rate			1.20%	0.50%	0.70%							0.41%
Expected volatility												39.90%
Expected life												3 years 7 months 6 days
Dividend yield, rate												0.00%
Weighted average fair value of stock options, per share												$ 7.07
Increase in developed technology													135,000,000
Reduction in process research and development													110,000,000
Adjustment to valuation of intangibles													2,000,000
Agreement to sell LIFECODES business to Immucor															85,000,000
Contingent payment of an additional amount based on future revenue results															10,000,000
Gain on the sale of LIFECODES business	5,300,000	900,000	(5,500,000)	0	0					900,000
Assets held-for-sale									2,800,000		2,800,000
Discount rate used for cash flow projections																10.00%	12.00%
In-process research and development								117,000,000					117,000,000
IPR&D Projects												4		6
In-process research and development, value												94,000,000
Discount rate												12.00%
Expected number of years for project completion												3 years
Finite-lived intangible assets, estimated useful life, years																				13 years 4 months 24 days	13 years	11 years
Fair value adjustment to increase the carrying amount																		107,900,000	70,600,000
Revenue earned by Gen-Probe post-acquisition														89,500,000
Pre-tax income (loss) from Gen-Probe post-acquisition														47,700,000
Cash paid								3,967,900,000
The excess of the purchase price over the fair value recorded to goodwill	$ 2,810,800,000		$ 2,810,800,000	$ 2,814,500,000				$ 1,641,000,000